

Presentation of the proposed Board

The Nomination Committee's proposal for the Board of Directors of BioArctic AB prior to the Annual General Meeting 2024

NEW ELECTION

Anna-Lena Engwall (1971)

Proposed as director:	2024
Holdings in BioArctic:	-
Education:	Bachelor of Science in Nursing, Karolinska Institute, Stockholm. Diploma DIHM Marketing & Mangement, IHM Business School, Stockholm.
Other current assignments:	-

Anna-Lena Engwall holds a degree in nursing from Karolinska Institutet and a degree in market economics from IHM Business School. She has more than 25 years of experience in the life science and pharmaceutical industry with leading roles in commercialization, marketing and business development and has during her career held several positions at AstraZeneca, Shire and Novartis. Her broad experience, industry knowledge and significant network are expected to provide the board with additional valuable expertise. Anna-Lena Engwall has previously been a member of the board of directors of Lif, Läkemedelsindustriföreningens Service AB.

Anna-Lena Engwall is independent in relation to the company, its executive management and the major shareholders of the company.

RE-ELECTION

Eugen Steiner (1954)

Proposed chairman of the Board

Chairman since:	2023
Director since:	2017
Holdings in BioArctic:	80,000 B-shares
Education:	Karolinska Institutet (Sweden) (licensed physician, Doctor of Clinical Pharmacology).
Other current assignments:	Chairman of the Board Empros Pharma AB. Board member of Inbox Capital AB and Stockholm School of Entrepreneurship.

Eugen Steiner is independent in relation to the company, its executive management and the major shareholders of the company.

Cecilia Edström (1966)

Director since:	2023
Holdings in BioArctic:	6,500 B-shares
Education:	Bachelor of Science in Finance and Economics from the Stockholm School of Economics
Other current assignments:	Founder and CEO ceed konsult AB. Board member of Flerie Invest AB, A3P Biomedical AB and Neonode Inc. Advisory Board Member, European Patient Safety Foundation (EUPSF).

Pär Gellerfors (1947)

Director since:	2003
Holdings in BioArctic:	5,759,998 A-shares and 13,343,201 B-shares through Ackelsta AB.

Education: Bachelor's degree in chemistry; PhD in chemistry; Associate Professor of Biochemistry, all from Stockholm University, Sweden

Other current assignments: Founder and Board member of MPG Medical AB, Ackelsta AB and LPB Sweden AB.

Pär Gellerfors controls 21.6 percent of the share capital and 32.6 percent of the votes in the company and has previously been active in the company's management. Pär Gellerfors therefore is not independent in relation to the company, its executive management nor the major shareholders of the company.

Lars Lannfelt (1949)

Director since: 2003

Holdings in BioArctic: 8,639,998 A-shares and 20,885,052 B-shares through Demban AB.

Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.

Other current assignments: Board member of Demban AB and LPB Sweden AB.

Lars Lannfelt controls 33.4 percent of the share capital and 49.2 percent of the votes in the company and is employed in the company. Lars Lannfelt thereby is not independent in relation to the company, its executive management nor the major shareholders of the company.

Lotta Ljungqvist (1961)

Director since: 2021

Holdings in BioArctic: 3,159

Education: Degree in biochemistry from KTH Royal Institute of Technology in Stockholm, Sweden. Doctorate in biochemical technology.

Other current assignments: Board member of Atlas Antibodies AB, Genovis AB, Arocell AB, NorthXBiologics AB and BioLamina AB. Chairman of the Royal Swedish Academy of Engineering Sciences' (IVA) department X Biotechnology and chairman of SwedenBio.

Lotta Ljungqvist is independent in relation to the company, its executive management and the major shareholders of the company.

Mikael Smedeby (1968)

Director since: 2018

Holdings in BioArctic: 27,270 B-shares

Education: Master of Laws, Uppsala University, Sweden. Military Reserve Officer training at InfoOHS and InfSS.

Other current assignments: Lawyer and Partner in the law firm Lindahl. Chairman of the board in Coeli Holding AB (including some subsidiaries), Salléngruppen AB (including subsidiaries) and in Uppsala Akademiförvaltning. Board member of Rarity Bioscience AB, Sirius Fotboll and Smedeby Förvaltning AB.

Mikael Smedeby is independent in relation to the company, its executive management and the major shareholders of the company.

The information regarding board assignments and holdings of shares is as of 31 March 2024 and also includes any changes thereafter known to the company.